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Background: Unresectable or metastatic cutaneous squamous 
cell cancers (cSCCs) are rare but potentially life-threatening 
diseases. In this setting, systemic therapy has a palliative intent 
with limited benefit, but there is no established consensus 
regarding the proper management of this tumour. This 
retrospective study aimed to review outcomes in patients with 
non-curable cSCC treated with platinum-based chemotherapy 
and cetuximab.
Methods: We considered 12 consecutive patients treated 
between June 2010 and March 2016. All patients had received 
previous treatment for the local disease.
Results: The overall response rate was 50%, and the disease 
control rate was 67%. Median progression-free survival and 
overall survival were 6.6 (95% confidence interval [CI]: 1.9–8.4) 
and 14.6 (95% CI: 9.4–20.1) months, respectively. The median 
duration of response was 4.8 months (95% CI: 1.2–5.9). The most 
frequent toxicities were skin reactions (58%; grade 3: 25%) and 
anaemia (10%). No grade 4 toxicities were observed.
Conclusions: Cetuximab and platinum-based chemotherapy 
were shown to be feasible and active in cSCC, with an 
acceptable toxicity profile, even if with a limited duration of 
response.
Keywords: cetuximab, combination, cSCC, platinum-based 
chemotherapy.
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Cutaneous squamous cell cancers (cSCCs) are frequent in 
the Caucasian population, accounting for approximately 
20% of non-melanoma skin cancers.1 In the last few decades, 
population-based studies have highlighted a rapid global 
increase in cSCC incidence.2,3 Typically, cSCC can be cured 
with surgical excision or radiotherapy. More options for early 
lesions are Mohs surgery, curettage, cryosurgery, laser, and 
photodynamic therapy. Nonetheless, it can recur and rarely 
metastasize (1.9–2.6%).4 cSCC not amenable to curative 
treatments can lead to physical disfigurement with a major 
impact on the patient’s quality of life, resulting in a life-
threatening disease. At present, in addition or as an alternative to 
radiotherapy, chemotherapy (CT) is reserved in case of recurrent 
or metastatic (R/M) disease, but data supporting efficacy are still 
limited without established treatment standards.5–7
The most common chemotherapeutic agent used in the 
non-curable setting is cisplatin, which has been used as a 
single agent or combined with other drugs (e.g. 5-fluorouracil, 
doxorubicin, or bleomycin).8–10
The epidermal growth factor receptor (EGFR) is highly expressed 
in many epithelial tumours including cSCC11; this glycoprotein 
plays a crucial role in signal transduction pathways that regulate 
key cellular functions.12 Therefore, anti-EGFR agents have been 
investigated in unresectable/metastatic cSCC. In this setting, 
monotherapy with both anti-EGFR antibodies, cetuximab and 
panitumumab, and tyrosine kinase inhibitors, such as gefitinib, 
erlotinib, and dacomitinib, showed some activity, with a range 
of response between 10% and 31%.12–20 The combination 
of cisplatin-based chemotherapy and cetuximab is widely 
employed in head and neck squamous cell carcinoma, where it 
provided a survival benefit over chemotherapy alone.
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In a French retrospective study, the authors evaluated patients 
with locally advanced, non-metastatic cSCC who were  
non-operable because no complete resection was possible 
or due to the risk of critical cosmetic or functional outcomes. 
Patients received neoadjuvant CT with cetuximab, platinum 
salt, and 5-fluorouracil, to increase the indication for surgery. 
This combination led to the resection of the majority (92%) 
of previously unresectable cSCC.21 The potential efficacy of 
cetuximab in this setting has also been shown in other small 
reports, investigating the use of cetuximab in association with 
radiotherapy (RT) or in patients who are refractory to  
platinum-based regimens.5,18,22
However, at present, there are no data, to our knowledge, 
regarding the concurrent use of platinum and cetuximab in 
R/M cSCC patients. Therefore, we report herein a retrospective 
series of patients treated with this combination, to review its 
safety profile and feasibility, and to be considered as a historical 
comparator with immunotherapeutic agents, which have 
been recently reported or are in study in the same setting of 
disease.23
Patients and methods
After approval by the Institutional Review Board (Fondazione 
IRCCS Istituto Nazionale dei Tumori, Milano, Italy), we analysed 
patient data recorded on an electronic cancer database, thus 
identifying all the patients treated at our Institution between 
June 2010 and March 2016 with a combination of platinum-
based CT and cetuximab. All information was de-identified 
for the analysis of data and manuscript drafting. All patients 
who were not amenable to curative treatment due to rapid 
progressing disease or unfeasibility of curative approaches  
and fit for CT received this protocol. In total, we identified  
12 patients, whose characteristics are listed in Table 1. Response 
to systemic therapy was assessed according to RECIST 1.1.
Cetuximab was administered weekly in association with 
3-weekly cisplatin (five patients, one patient also received 
5-fluorouracil) or carboplatin (seven patients) when cisplatin 
was contraindicated (e.g. patient frailty and impaired renal 
function).
Males were predominant (11 males/1 female), and the median 
age was 73 years (range: 46–82). ECOG performance status 
(PS) was 0 in two patients, 1 in nine patients, and 2 in one 
patient. Most patients (83%) had a primary disease localized in 
the head and neck area and the remaining ones in the gluteal 
region. Most patients had T3–T4 local disease (60%), whilst 
node metastases were present in half of them. Four patients 
had metastatic disease at the start of treatment. Histological 
characteristics showed poorly differentiated aspects in one 
case and pseudosarcomatoid traits in two cases. All patients 
received previous surgery, whilst RT was performed in 7 out  
of 12 patients. Amongst patients who had not received 
radiotherapy, three had rapid disease progression after surgery, 
which contraindicated postoperative radiation; in the other two 
Table 1. Patients’ characteristics.
n %
Gender:
•	 Male 11 92
•	 Female 1 8
Median age (range); years 74 (46–82)
ECOG performance status:
•	 0 2 17
•	 1 9 75
•	 2 1 8
Primary localization:
•	 H&N 10 83
•	 Gluteal region 2 17
Local disease:
•	 No local recurrence 1 8
•	 T1 0 0
•	 T2 3 25
•	 T3 6 50
•	 T4 1 8
•	 NA 1 8
Node involvement:
•	 N0 5 42
•	 N1 3 25
•	 N2 3 25
•	 NA 1 8
Metastatic at treatment start 4 33
Histotype:
•	 Histological subtypes of SCC 12 100
•	 Invasive SCC 9 75
•	 Poorly differentiated SCC 1 8





•	 Surgery 12 100
•	 Radiotherapy 6 50
•	 Chemotherapy 1 8
•	 TKI 1 8
•	 Sirolimus 1 8
•	 Metastasectomy 1 8
•	 CTRT 1 8
Chemotherapy associated 
with cetuximab:
•	 Cisplatin 4 33
•	 Carboplatin 7 58
•	 Cisplatin + 5-fluoruracil 1 8
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cases, there was no clinical indication to radiotherapy. Other 
previous treatments consisted of metastasectomy (8%), CT with 
cisplatin and 5-fluorouracil (8%), concurrent chemoradiation 
(8%), gefitinib (8%), and sirolimus (8%). Median disease-free 
interval from the first curative treatment was 4.5 months  
(95% confidence interval [CI]: 2.0–18.9). One-third of patients 
were metastatic at the start of the treatment.
Results
In the period of enrolment, 12 patients were recruited, and only 
15% of patients presenting with recurrent and/or metastatic 
disease were judged unfit for CT and received best supportive 
care. All patients experienced at least one treatment-related 
adverse event. Skin reactions (58%) and anaemia (50%) were 
the most frequent toxicities; neutropenia, thrombocytopenia, 
and nausea accounted for less than 20%. Grade 3 adverse 
events occurred in 25% of patients (skin rash 25% and 
neutropenia 8%), and no grade 4 or grade 5 toxicities were 
observed.
Amongst 12 patients, the overall response rate (RR) was 50%: 
complete response 1/12 (8%) and partial response 5/12 (42%). 
Two patients had stable disease leading to a disease control 
rate of 67% in the entire study population. Moreover, 4 out of 
12 patients (33.3%) progressed during treatment without any 
clinical benefit, including 1 patient with a pseudosarcomatous 
tumour who had a rapid disease progression after the first 
cycle of treatment. One frail patient (PS 2) received carboplatin 
obtaining a partial response, and the treatment was tolerated 
though complicated by G3 myelotoxicity. Figure 1 shows a 
case of partial response to treatment (three-weekly carboplatin 
+ cetuximab). This exemplary patient received five cycles of 
carboplatin + cetuximab achieving a PR and had a clinical 
benefit in terms of pain control. He received radiotherapy 
afterwards, and progression-free survival (PFS) was 9.5 months. 
After systemic treatment, 6 patients (50%) underwent further 
local treatments: 3 patients (25% of the total) received surgery 
and 4 patients (33%) received RT; of these 6 patients, 4 had 
obtained a response (CR + PR) to drug combination. Median 
duration of response was 4.8 months (95% CI: 1.2–5.9). Median 
PFS and overall survival (OS) were 6.6 (95% CI: 1.9–8.4) and 
14.6 (95% CI: 9.4–20.1) months, respectively. The longest OS 
was observed in a patient who underwent surgery despite of 
disease progression (25.3 months) and in 3 responding patients 
(1 complete response – 84.7 months and 2 partial responses – 
20.1 and 17.6 months), 2 of the latter were consolidated with a 
local treatment after CT (surgery and RT with cetuximab). No 
differences in PFS (Figure 2) or OS between responders and 
not responders were reported (PFS: 6.9 months in responders 
[95% CI 4.6–9.5] versus 3.6 months in non-responders [0.7–10.9]; 
p=0.88. OS: 17.6 [9.4–NR] versus 14.5 months [2.6–25.3]; p=0.2) 
(Figure 2).
Patients with pseudosarcomatoid differentiation had a dismal 
prognosis (PFS <2 months).
Discussion
Consensus on the treatment strategy for the management of 
advanced cSCC is still to be reached. Recently, EGFR inhibition 
by cetuximab has shown some efficacy in the non-operable 
setting.5,6,18,22 However, information on the feasibility of 
cetuximab in combination with platinum-based CT is lacking.
The combination of cetuximab and platinum-based CT 
showed to be feasible and active in advanced cSCC. The 
toxicity profile was acceptable, considering the overall fragile 
patient population. In fact, the series was mainly composed of 
heavily pretreated patients with advanced age and recurrent 
tumours, all conditions potentially exposing the patients to a 
higher toxicity risk. Notwithstanding, the adverse events were 
common but of limited severity; this could be explained by the 
choice to combine a mono-CT with cetuximab in almost all the 
cases and the use of carboplatin instead of cisplatin in more 
than half of the patients, therefore tailoring the treatment to 
the frailty of the patients. Because of this tailored approach, 
Figure 1. A case of partial response, obtained 2 months after treatment initiation. 
(A) Baseline and (B) 2 months.
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our results, identifying more than 90% of the patients treated 
with chemotherapy and targeted treatment able to undergo 
curative surgery. In this French series, patients had no distant 
metastases and more than 40% of the cases were naïve to any 
therapy.
The same authors reported median PFS of 8.5 months in 
operated patients after the use of neo-adjuvant cetuximab 
combined with a platinum salt and 5-fluorouracil. Keeping in 
mind the different populations of the two studies, the PFS is not 
so different when compared to the one obtained in our series 
of R/M patients (6.6 months). This fact reinforces the concept of 
a short-lived duration of response with the currently available 
systemic treatments.
Therefore, locally advanced or R/McSCCs not amenable to 
curative approaches remains an unmet need for clinical 
oncology.
Recent data showed a promising activity of immune 
checkpoint inhibitors in locally advanced or metastatic cSCC. 
Approximately half of the patients treated with cemiplimab 
(anti-PD-1 agent) within a phase I–II trial obtained partial or 
complete responses. Responses were rapid (median time to 
response: 1.9 months) and durable in most patients; in fact, in 
more than half of the patients duration of response exceeded  
6 months and the estimated probability of PFS at 12 months was 
53% (95% CI: 37–66), whilst the same figure for OS was 81%.28 
Median duration of response and median OS were not reached.
Our results may help to evaluate the position of 
immunotherapy in the course of the disease. Other trials 
employing checkpoint inhibitors in the recurrent/metastatic 
setting, as well as in adjuvant setting, are ongoing. New 
knowledge about immunotherapy makes it necessary to 
reconsider the role and timing of all available systemic 
therapy was heterogeneous in our small number of patients 
(i.e. patients were in different stages and had received several 
types of previous treatment) and this limited reliability and 
interpretation of results. The possible underestimation of 
adverse events collection in a retrospective series should be 
also considered as a limitation of the study. Another limitation 
is the lack of data on quality of life and a systematic evaluation 
of the treatment benefit.
In comparison to the previous series of R/M cSCC patients 
treated with single anti-EGFR agents (RR: 10–31%),12–16 the 
combination of cetuximab and CT showed higher responses 
(50%). Conversely, CT achieved higher responses rates when 
doublet or triplet regimens were used (RR: 37.5–85.7%),8,10,24 
whilst results with mono-CT are dismal (RR: 14.3%).25
Median PFS was comparable to those of patients treated with 
anti-EGFR monotherapies (range: 3.8–8 months).12–16 Therefore, 
the benefit from the use of this drug combination appears 
to be mainly an increased response rate. However, achieving 
responses in these aggressive and destructive tumours 
cannot be underestimated, as it could reflect in symptom 
improvement and thus a better quality of life for patients. 
Moreover, most patients (83%) showing a response to CT and 
anti-EGFR agent subsequently received surgery or RT. This 
emphasizes the benefit of systemic treatments in increasing 
the rate of patients initially not amenable to curative therapies 
who become candidates to these approaches, although we 
cannot rule out that these patients presented a less aggressive 
disease than the others. In our experience, two patients had 
pseudosarcomatous tumours, and they had either no response 
or a very short response. This could be expected, as this type 
of tumour presents with a lower expression of EGFR, and is 
less responsive to chemotherapy.26,27 Findings reported in a 
retrospective series of cases by a French group20 were similar to 
Figure 2. Progression-free survival curves of responder and  
non-responder patients.
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treatments. Treatment combinations or sequences should be 
exploited to maximize the response to immunotherapy and to 
tackle primary and acquired resistance.
Considering the limitations of our retrospective analysis 
conducted in a limited number of cases and on a quite 
heterogeneous population, we presented the outcome of 
a series of patients with RM cSCCs not amenable to salvage 
approaches and treated with a combination of cetuximab and 
platinum-based chemotherapy. Toxicity profile, response rate, 
and rescue of salvage local treatments are the main strengths 
of this therapy, whilst short-lived responses and PFS are the 
corresponding drawbacks.
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